Top 3 Losing ASX Stocks Today: Life360, Amotiv & Starpharma Under Pressure

These are the top three losing ASX stocks, led by weakened results, funding issues and lackluster growth.

Life360 Inc. (ASX: 360)

is one of the top losing ASX technology stock, which is near its 52-week low, with a market capitalisation of $6.15B and no dividend yield.

360 has announced on 11 August 2026, its second-quarter results for the period ended in June 2026. Life360 reported revenue for the quarter reached $159M, up 38% YoY. The operating expense increased by 43% to $127M, primarily driven by R&D and S&M investment supporting advertising platform scaling and international expansion. 360 struggles with profitability as net income declined massively by 28% to $5.1M.

Life360 reported a weaker balance sheet, led by liquidity issues as cash and cash equivalents declined by 38% YoY to $269.8M, whereas inventory increased to $14.7M from $9.9M from June 2025 and accounts receivable increased to $98.6M from $80.7M, highlighting a potential red flag in earnings quality.

Amotiv Limited (ASX: AOV)

is one of the top losing ASX stocks, which is near its 52-week low, with a market capitalisation of $875.38M and a dividend yield of 6.42%.

AOV has announced, on 11 August 2026, its financial result for FY26 for the period ending in June 2026. Amotiv has reported muted growth, with revenue increasing by only 2.7% YoY to $1.02B. The gross margin declined by 100 bps to 42.8%. The underlying EBITDA also showed weak growth of 1.6% YoY to $230M and underlying EBITA also grew by 1.6% YoY. This shows that the company has delivered weak growth during FY26, which led to the stock decline.

AOV management expects a modest revenue and underlying EBITA growth in FY27, led by growing offshore revenue, pricing and Amotiv Unified offsetting subdued ANZ conditions.

AOV operates in a weak market with low revenue growth and has pressure in its 4WD business, resulting in weaker financial results.

Starpharma Holdings Limited (ASX: SPL)

is one of the top losing ASX healthcare stocks, with a market capitalisation of $284.13M.

SPL has announced, on 11 August 2026, the successful completion of the fully underwritten 1 for 7.5 renounceable pro rata entitlement offer of new fully paid ordinary shares to raise $32M. Eligible shareholders who applied for new shares under the oversubscription facility can expect to receive the full quantum of their applications.

SPL received strong support from the existing shareholders with a take-up rate of approximately 99%, including $5.4M of applications under the oversubscription facility. Starpharma has to issue 56 million new shares under the entitlement offer, which is expected to be allotted by 11 August 2026 (today).

The entitlement offer may look good from the outside, but it will definitely dilute equity if existing shareholders do not participate. SPL is still a loss-making company; additional capital raised will be used in clinical development, not immediate revenue-generating assets, which is highly subject to regulatory issues.

Conclusion

These three stocks are among the top losing ASX companies due to low growth, bad revenue visibility, profitability issues and weak liquidity. 360 has profitability issues and high expectations, which leads them to a spark-fall in stock price. AOV is operating in a low-growth market and has weak operational efficiency, and SPL is a loss-making company with funding issues.

(Source: Company Announcements)